---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-031899"
form_type: "8-K"
ticker: "DTIL"
cik: "0001357874"
company_name: "PRECISION BIOSCIENCES INC"
filed_at: "2023-07-06T23:59:59+00:00"
generated_at: "2026-06-13T11:38:26.568285+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Precision BioSciences amends Prevail collaboration; milestones cut to $390-395M, cash runway to Q1 2025

## Summary
- Preclinical and IND-enabling activities shifted to Prevail; manufacturing of initial clinical supply also Prevail's responsibility.
- Maximum milestone payments per licensed product reduced from $420M to $390-395M reflecting changed cost sharing.
- Prevail continues to fund development and commercialization; royalties and nomination fees unchanged.
- Company expects existing cash, operational receipts and credit to fund operations through Q1 2025.

## SEC filing metadata
- accession: 0000950170-23-031899
- form_type: 8-K
- ticker: DTIL
- cik: 0001357874
- company_name: PRECISION BIOSCIENCES INC
- filed_at: 2023-07-06T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 1.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/0000950170-23-031899-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/dtil-20230630.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-031899
- JSON: https://secwatch.observer/filing/0000950170-23-031899.json
- Plain text: https://secwatch.observer/filing/0000950170-23-031899.txt

## Key facts
- Material Agreements
  PRECISION BIOSCIENCES INC amended A&R Development and License Agreement with Prevail Therapeutics Inc. valued at up to an aggregate of $390 million to $395 million per licensed product (effective 2023-06-30).
  - Action: amendment
  - Agreement: collaboration
  - Counterparty: Prevail Therapeutics Inc.
  - Value: up to an aggregate of $390 million to $395 million per licensed product
  - Effective: 2023-06-30
  source text: On June 30, 2023, Precision BioSciences, Inc. (the “Company”) entered into an amended and restated development and license agreement (the “A&R Development and License Agreement”) with Prevail Therapeutics Inc. (“Prevail”), a wholly owned subsidiary of Eli Lilly and Company (“Lilly”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1357874/000095017023031899/0000950170-23-031899-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.